Autologous hematopoietic stem cell transplantation with TBE conditioning in patients with primary central nervous system lymphoma
- VernacularTitle:TBE方案预处理自体造血干细胞移植治疗原发中枢神经系统淋巴瘤的临床分析
- Author:
Junli CHEN
1
;
Yi MA
1
;
Ruiqing ZHAO
1
;
Xiubin XIAO
1
;
Xilin CHEN
1
;
Shunzong YUAN
1
;
Shihua ZHAO
1
;
Yun LU
1
;
Honghao GAO
1
;
Yueqi WANG
1
;
Hua YIN
1
;
Nana CHENG
1
;
Pan FENG
1
;
Xiaoran BAI
1
;
Wenrong HUANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Hematopoietic stem cell transplantation; Primary central nervous system lymphoma; Thiotepa; Busulfan; Etoposide
- From: Chinese Journal of Hematology 2025;46(11):1038-1043
- CountryChina
- Language:Chinese
- Abstract: Objective:To assess the safety and efficacy of thiotepa, busulfan, and etoposide (TBE) conditioning followed by autologous hematopoietic stem-cell transplantation (TBE auto-HSCT) in primary central nervous system lymphoma (PCNSL) patients.Methods:Clinical data from 27 PCNSL patients who received TBE auto-HSCT at the Fifth Medical Center of PLA General Hospital between November 1, 2021, and April 30, 2024, were retrospectively analyzed.Results:Twenty-seven patients [16 males, 11 females; median age 57 (23–72) years] were included, with 12 (44.4%, 12/27) over 60. Twenty-five had newly diagnosed PCNSL and 2 were relapsed. Median time from diagnosis to transplantation was 6.9 (5.0–10.0) months. TBE auto-HSCT increased complete remission (CR) rate from 63.0 to 96.3% ( P= 0.005), and 9 of 10 patients in partial remission achieving CR post-transplant. Median follow-up was 24.5 months (range 2.0–36.0). Two-year progress-free and OS rates were (87.2±6.9) % and (88.6±6.2) %, respectively. Common grade 3 nonhematologic adverse events were diarrhea (18.5%, 5/27) and bacterial infections (14.8%, 4/27). One patient (64 years old) died from carbapenem-resistant Enterobacteriaceae infection within 2 months post-transplant, yielding a 100-day treatment-related mortality of 3.7% (1/27) . Conclusion:TBE-conditioned high-dose chemotherapy with auto-HSCT is effective, safe, and well-tolerated in PCNSL patients, including the elderly.
